Investors purchased shares of Gilead Sciences, Inc. (NASDAQ:GILD) on weakness during trading hours on Thursday after an insider sold shares in the company. $154.37 million flowed into the stock on the tick-up and $90.06 million flowed out of the stock on the tick-down, for a money net flow of $64.31 million into the stock. Of all stocks tracked, Gilead Sciences had the 8th highest net in-flow for the day. Gilead Sciences traded down ($0.57) for the day and closed at $81.17Specifically, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total value of $1,122,300.00. Following the sale, the executive vice president now directly owns 77,363 shares in the company, valued at approximately $5,788,299.66. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Gregg H. Alton sold 30,000 shares of Gilead Sciences stock in a transaction dated Thursday, January 11th. The shares were sold at an average price of $79.00, for a total transaction of $2,370,000.00. Following the completion of the sale, the executive vice president now owns 57,114 shares in the company, valued at $4,512,006. The disclosure for this sale can be found here. Over the last quarter, insiders sold 591,666 shares of company stock worth $44,466,567. 1.30% of the stock is currently owned by insiders.

GILD has been the topic of several recent research reports. Berenberg Bank set a $96.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Thursday, October 19th. Mizuho reiterated a “buy” rating on shares of Gilead Sciences in a research report on Friday, September 29th. William Blair reiterated a “buy” rating on shares of Gilead Sciences in a research report on Thursday, October 19th. JPMorgan Chase & Co. set a $85.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Wednesday, October 25th. Finally, Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and lifted their price objective for the company from $73.67 to $94.00 in a research report on Thursday, November 30th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eighteen have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $85.53.

The company has a market cap of $106,000.00, a PE ratio of 9.23, a price-to-earnings-growth ratio of -1.71 and a beta of 1.13. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping the consensus estimate of $2.13 by $0.14. The business had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The firm’s quarterly revenue was down 13.2% compared to the same quarter last year. During the same period last year, the firm posted $2.75 earnings per share. equities research analysts expect that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Thursday, December 28th. Stockholders of record on Friday, December 15th were given a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.56%. The ex-dividend date was Thursday, December 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 23.66%.

Several institutional investors have recently added to or reduced their stakes in GILD. City Holding Co. increased its position in shares of Gilead Sciences by 4.0% in the second quarter. City Holding Co. now owns 23,895 shares of the biopharmaceutical company’s stock worth $1,691,000 after acquiring an additional 914 shares in the last quarter. Koshinski Asset Management Inc. boosted its holdings in shares of Gilead Sciences by 106.7% during the second quarter. Koshinski Asset Management Inc. now owns 7,813 shares of the biopharmaceutical company’s stock worth $553,000 after purchasing an additional 4,033 shares during the period. Atria Investments LLC boosted its holdings in shares of Gilead Sciences by 27.7% during the second quarter. Atria Investments LLC now owns 15,137 shares of the biopharmaceutical company’s stock worth $1,071,000 after purchasing an additional 3,285 shares during the period. ANTIPODES PARTNERS Ltd boosted its holdings in shares of Gilead Sciences by 40.2% during the second quarter. ANTIPODES PARTNERS Ltd now owns 1,095,357 shares of the biopharmaceutical company’s stock worth $77,529,000 after purchasing an additional 313,939 shares during the period. Finally, Kissinger Financial Services LLC acquired a new stake in shares of Gilead Sciences during the second quarter worth approximately $347,000. 75.95% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This article was first published by Daily Political and is owned by of Daily Political. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.dailypolitical.com/2018/01/18/traders-buy-gilead-sciences-gild-on-weakness-on-insider-selling.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.